The PRIME designation by the European Medicines Agency is a significant regulatory milestone that can accelerate the development and review process of Isaralgagene Civaparvovec. This not only validates the potential of the treatment but also positions Sangamo Therapeutics favorably in the biotech and gene therapy market. The positive regulatory news is likely to be viewed favorably by investors, potentially leading to a short-term uptick in SGMO's stock price due to increased investor confidence in the company's pipeline and its ability to navigate the regulatory landscape successfully.